RT Journal Article
T1 IBUPROFEN AFTER IMPACTED LOWER THIRD MOLAR EXTRACTION: A RANDOMIZED CONTROLLED CLINICAL TRIAL
A1 Vallecillo, Cristina
A1 Vallecillo-Rivas, Marta
A1 Galvez, Rafael
A1 Vallecillo-Capilla, Manuel
A1 Olmedo-Gaya, Maria Victoria
K1 Pain management
K1 Analgesia
K1 Acute pain
K1 Multimodal treatment
K1 Oral surgery
K1 To-severe pain
K1 Dexketoprofen trometamol
K1 Analgesic efficacy
K1 Safety
K1 Tramadol
K1 Combination
K1 Management
K1 Difficulty
K1 Ketoprofen
K1 Placebo
AB ObjectiveImpacted third molar extraction is associated with acute moderate-to-severe pain for up to 48 hours post-surgery. This trial was designed to compare the analgesic effectiveness, swelling, and adverse events after impacted third molar surgery following multimodal therapy with 75 mg tramadol hydrochloride plus 25 mg dexketoprofen or monotherapy with 400 mg ibuprofen.MethodsSeventy-two patients were randomly assigned to receiving ibuprofen (n = 36) or tramadol-dexketoprofen (n = 36). Postoperative pain intensity and swelling were measured using a visual analog scale (VAS); pain relief experienced was reported using a 4-point verbal rating scale; the rescue medication requirement, adverse effects, and global impression of the medication were recorded.ResultsNo statistically significant between-group difference in pain intensity was observed at any time point; however, pain relief was significantly higher in the tramadol-dexketoprofen treated-group at 6 and 36 hours. Self-reported verbal rating scale assessments showed significantly lower swelling in the tramadoldexketoprofen group at 24 hours post-surgery but not at 48 or 72 hours, and VAS swelling scores showed no significant between-group difference. The frequency of postoperative nausea and dizziness was significantly higher in the tramadoldexketoprofen group.ConclusionsMultimodal therapy proved more effective to manage moderate-severe pain after impacted third molar surgery in comparison to monotherapy. However, the improvement in relief must be balanced against the increased risk of adverse effects when considering this multimodal approach.
PB Elsevier inc
SN 1532-3382
YR 2021
FD 2021-11-21
LK https://hdl.handle.net/10668/26261
UL https://hdl.handle.net/10668/26261
LA en
DS RISalud
RD Apr 10, 2025